Cancers, Vol. 15, Pages 1660: Pragmatic, Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone: The PROSPER Study Rationale and Design

Cancers, Vol. 15, Pages 1660: Pragmatic, Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone: The PROSPER Study Rationale and Design Cancers doi: 10.3390/cancers15061660 Authors: Bradford S. Hoppe Ivy A. Petersen Benjamin K. Wilke Todd A. DeWees Reiko Imai Eugen B. Hug Maria Rosaria Fiore Jürgen Debus Piero Fossati Shigeru Yamada Ester Orlandi Qing Zhang Cihang Bao Katharina Seidensaal Byron C. May Anna C. Harrell Matthew T. Houdek Laura A. Vallow Peter S. Rose Michael G. Haddock Jonathan B. Ashman Krista A. Goulding Steven Attia Sunil Krishnan Anita Mahajan Robert L. Foote Nadia N. Laack Sameer R. Keole Chris J. Beltran Eric M. Welch Mohammed Karim Safia K. Ahmed Surgical treatment of pelvic sarcoma involving the bone is the standard of care but is associated with several sequelae and reduced functional quality of life (QOL). Treatment with photon and proton radiotherapy is associated with relapse. Carbon ion radiotherapy (CIRT) may reduce both relapse rates and treatment sequelae. The PROSPER study is a tricontinental, nonrandomized, prospective, three-arm, pragmatic trial evaluating treatments of pelvic sarcoma involving the bone. Patients aged at least 15 years are eligible for inclusion. Participants must have an Eastern Cooperative Oncology Group Performance Status score of two or le...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Study Protocol Source Type: research